Effectiveness and safety of rapid clozapine titration in schizophrenia

Acta Psychiatrica Scandinavica

Volumn 130, Issue 1, 2014, Pages 25-29

  Ifteni, P ^a   Nielsen, J ^b   Burtea, V ^a   Correll, C U ^c,d,e   Kane, J M ^c,d,e   Manu, P ^c,d,e  

^a TRANSILVANIA UNIVERSITY OF BRASOV   (Romania)

^b Aalborg Psykiatriske Sygehus   (Denmark)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

^d DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Clozapine; Rapid titration; Schizophrenia; Symptom control

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSITIVE SYNDROME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEIZURE; TREATMENT FAILURE; TREATMENT RESPONSE; CLINICAL PROTOCOL; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CLINICAL PROTOCOLS; CLOZAPINE; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902080617     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12241     Document Type: Article

References (24)

1. Ramachandraiah CT, Subramaniam N, Tancer M. The story of antipsychotics: past and present. Indian J Psychiatry 2009;51:324-326.
2. Hippius H. The history of clozapine. Psychopharmacology 1989;99(Suppl):S3-S5.
3. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B. Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991;17:247-261.
4. Idanpaan-Heikkila J, Alhava E, Olkinoura M, Palva IP. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol 1977;11:193-198.
5. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
6. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39-60.
7. Meltzer HY, Alphs L, Green AI et al. International suicide prevention trial study group. Clozapine treatment for suicidality in schizophrenia: international suicide prevention trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91.
8. Nielsen J, Correll CU, Manu P, Kane JM. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 2013;74:603-613.
9. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16-24.
10. Pai NB, Vella SC. Reason for clozapine cessation. Acta Psychiatr Scand 2012;125:39-44.
11. Falzer PR, Garman DM. Optimizing clozapine through clinical decision making. Acta Psychiatr Scand 2012;126:47-58.
12. Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-371.
13. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norchlozapine plasma concentrations and clinical response of treatment-refractoy schizophrenic patients. Am J Psychiatry 1991;148:231-235.
14. Aitchison KJ, Jann MW, Zhao JH et al. Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice. J Psychopharmacol 2000;14:353-359.
15. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012;141:173-178.
16. Association American Psychiatric. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: American Psychiatric Association; 2000, Text Revision.
17. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
18. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ No ADM 76-338). Rockville, MD: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976;218-222.
19. Cohen D, Bogers JP, Vandijk D, Bakker B, Schulte PF. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry 2012;73:1307-1312.
20. Haas SJ, Hill R, Krum H et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57.
21. Merrill DB, Dec GW, Goff DC. Adverse cardiac drug effects associated with clozapine. J Clin Psychopharmacol 2005;25:32-41.
22. Ruprecht R, Soyka M, Grohmannr R, Ruther E, Moller HJ. Considerations in the combination of clozapine and benzodiazepines. Nervenarzt 2004;75:857-860.
23. Nielsen J, Damkier P, Lublin H, Taylor D. Optimizing clozapine treatment. Acat Psychiatr Scand 2011;123:411-422.
24. Nielsen J, Nielsen RE, Correll CU. Predictors of clozapine response in patients with treatment-refractory schizophrenia: results from a Danish Register Study. J Clin Psychopharmacol 2012;32:678-683.